MCM
ONCY

MAI Capital Management’s Oncolytics Biotech ONCY Stock Holding History

MAI Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$447 Hold
526
– – ﹤0.01% 4444
2025
Q4 		$460 Hold
526
– – ﹤0.01% 3849
2025
Q3 		$737 Hold
526
– – ﹤0.01% 3547
2025
Q2 		$407 Hold
526
– – ﹤0.01% 3794
2025
Q1 		$290 Hold
526
– – ﹤0.01% 3287
2024
Q4 		$481 Buy
+526
New +$547 ﹤0.01% 3300

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MAI Capital Management's ONCY Position: Q1 2026 in Review

MAI Capital Management held its Oncolytics Biotech (ONCY) position steady in Q1 2026 at 526 shares worth $447. The position accounts for ﹤0.01% of the portfolio, ranked #4444.

MAI Capital Management first reported a position in ONCY in Q4 2024 and has held it in 6 quarters since. The position peaked at $737 in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • MAI Capital Management held 526 shares of Oncolytics Biotech worth $447 as of Q1 2026.
  • MAI Capital Management left its Oncolytics Biotech share count unchanged in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4444 holding.
  • MAI Capital Management first reported a position in Oncolytics Biotech in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Oncolytics Biotech position peaked at $737 in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.